Denali reports 64% reduction in NfL with DNL310 in MPS II after 2 years

Denali Therapeutics Inc.

Mean serum NfL reduction of 64% (p<0.001) from baseline at 2 years in Phase 1/2 study (n=13).
FDA recommended assessment of NfL as a possible biomarker in neuronopathic MPS II.
Additional interim data from Phase 1/2 to be presented at SSIEM symposium in August 2023.
Global Phase 2/3 COMPASS study of DNL310 ongoing; management hosted investor webinar June 20.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.